Why is cardiovascular health important in menopausal women?

Climacteric

Volumn 9, Issue SUPPL. 1, 2006, Pages 13-18

  Simon, T ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cardiovascular disease; Estrogen; Menopause; Postmenopausal

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO;

ACUTE HEART INFARCTION; AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DIETARY INTAKE; ESTROGEN THERAPY; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE; MENOPAUSE; META ANALYSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SMOKING CESSATION; SURVIVAL RATE; SYSTEMATIC REVIEW;

ANTI-ARRHYTHMIA AGENTS; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MENOPAUSE; PROGNOSIS; RISK FACTORS; SEX FACTORS;

EID: 33747123311     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130600917757     Document Type: Conference Paper

References (40)

1. Rannevik G, Jeppsson S, Johnell O, Bjerre B, Laurell-Borulf Y, Svanberg L. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;21:103-13
2. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-8
3. Zanchetti A, Facchetti R, Cesana GC, Modena MG, Pirrelli A, Sega R. Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. J Hypertens 2005;23:2269-76
4. Masse PG, Dosy J, Cole DE, Evrovski J, Mahuren JD, Coburn SP. Elevation of plasma homocysteine in natural menopause can not be explained by a lack of vitamin coenzyme availability: relevance to the risk of cardiovascular disease. J Nutr Health Aging 2005;9:59-64
5. Mercuro G, Zoncu S, Cherchi A, Rosano GM. Can menopause be considered an independent risk factor for cardiovascular disease? Ital Heart J 2001;2:719-27
6. Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J Clin Endocrinol Metab 1997;82:1549-56
7. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Menopause-related changes in body fat distribution. Ann N Y Acad Sci 2000;904: 502-6
8. AHA (American Heart Association). Heart Disease and Stroke Statistics 2005 update. Available online at: http://americanheart.org. PDF accessed 24/11/05
9. WHO (World Health Organization). Mortality data 2002. Available online at: http://www.who.int. PDF accessed 27/11/05
10. Wenger NK. Coronary heart disease: the female heart is vulnerable. Prog Cardiovasc Dis 2003; 46:199-229
11. GCI (Global Cardiovascular infobase). Available online at: http://www.cvdinfobase.ca/. Accessed 27/11/05
12. INSERM. Service d'information sur les causes de deces (SC8). 1999
13. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet 1999;353:9-13
14. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure. Results from the cardiac insufficiency bisoprolol study (CIBIS II). Circulation 2001;103:375-80
15. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999;341:217-25
16. Simon T, Mary-Krause M, Cambou J, et al. Sex-age interaction after myocardial infarction: impact on hospital mortality and 1-year survival. Eur Heart J 2006;27:1282-8
17. Vaccarino V, Berkman LF, Krumholz HM. Long-term outcome of myocardial infarction in women and men: a population perspective. Am J Epidemiol 2000;152:965-73
18. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979;241:2035-8
19. Vilbergsson S, Sigurdsson G, Sigvaldason H, Sigfusson N. Coronary heart disease mortality amongst non-insulin-dependent diabetic subjects in Iceland: the independent effect of diabetes. The Reykjavik Study 17-year follow up. J Intern Med 1998;244:309-16
20. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336: 525-33
21. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11
22. Mallik S, Vaccarino V. Outcomes of thrombolytic therapy for acute myocardial infarction in women. Prog Cardiovasc Dis 2004;47:58-71
23. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86
24. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304
25. Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. Br Med J 2001;322:1-5
26. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-5
27. WHO (World Health Organization). Cardiovascular disease death rates in the world in 2000. Available online at: http://www.who.int
28. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
29. Graham IM. Guidelines on cardiovascular disease prevention in clinical practice: the European perspective. Curr Opin Cardiol 2005;20:430-9
30. Simon T, Boutouyrie P, Gompel A, et al. Rationale, design and methods of the CASHMERE study. Fundam Clin Pharmacol 2004;18:131-8
31. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44
32. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19: 791-804
33. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ (Clin Res Ed) 1988;296:313-16
34. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35
35. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anti-coagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease inmen at increased risk. Lancet 1998;351:233-41
36. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62
37. Kjeldson SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by hypertensive treatment and acetylsalicylic acid: The HOT study. J Hypertens 2000;18:629-42
38. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001;357:89-95
39. [Erratum Lancet 2001;357:1134]
40. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:56-65